The aminobisphosphonate zoledronic acid (ZA) is the most important antiresorptive agent for the treatment of multiple myeloma (MM)-related bone disease (BD). Osteonecrosis of the jaw (ONJ) is an important complication of ZA-treated MM patients (Vannucchi et al, 2005; Filleul et al, 2010). So far, the mechanism of ONJ pathogenesis has not been clearly elucidated.
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.
Mariamena Arbitrio;
2011
Abstract
The aminobisphosphonate zoledronic acid (ZA) is the most important antiresorptive agent for the treatment of multiple myeloma (MM)-related bone disease (BD). Osteonecrosis of the jaw (ONJ) is an important complication of ZA-treated MM patients (Vannucchi et al, 2005; Filleul et al, 2010). So far, the mechanism of ONJ pathogenesis has not been clearly elucidated.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
bjh0154-0529 (1).pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
196.85 kB
Formato
Adobe PDF
|
196.85 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
